Abstract:Background: Integrating radioactive and optical imaging techniques can facilitate the prognosis and surgical guidance for cancer patients. Using a single dual-labeled tracer ensures consistency in both imaging modalities. However, developing such molecule is challenging due to the need to preserve the biochemical properties of the tracer while introducing bulky labeling moieties. In our study, we designed a trifunctional chelate that facilitates the coupling of the targeting vector and fluorescent dye at opposite sites to avoid undesired steric hindrance effects. The synthesis of the trifunctional chelate N3-Py-DOTAGA-(tBu)3 (7) involved a five-step synthetic route, followed by conjugation to the linear peptidyl-resin 8 through solid-phase synthesis. After deprotection and cyclization, the near-infrared fluorescent dye sulfo-Cy.5 was introduced using copper free click chemistry, resulting in eTFC-01. Subsequently, eTFC-01 was labeled with [111In]InCl3. In vitro assessments of eTFC-01 binding, uptake, and internalization were conducted in SSTR2-transfected U2OS cells. Ex-vivo biodistribution and fluorescence imaging were performed in H69-tumor bearing mice. Results: eTFC-01 demonstrated a two-fold higher IC50 value for SSTR2 compared to the gold standard DOTA-TATE. Labeling of eTFC-01 with [111In]InCl3 gave a high radiochemical yield and purity. The uptake of [111In]In-eTFC-01 in U2OS.SSTR2 cells was two-fold lower than the uptake of [111In]In-DOTA-TATE, consistent with the binding affinity. Tumor uptake in H69-xenografted mice was lower for [111In]In-eTFC-01 at all-time points compared to [111In]In-DOTA-TATE. Prolonged blood circulation led to increased accumulation of [111In]In-eTFC-01 in highly vascularized tissues, such as lungs, skin, and heart. Fluorescence measurements in different organs correlated with the radioactive signal distribution. Conclusion: The successful synthesis and coupling of the trifunctional chelate to the peptide and fluorescent dye support the potential of this synthetic approach to generate dual labeled tracers. While promising in vitro, the in vivo results obtained with [111In]In-eTFC-01 suggest the need for adjustments to enhance tracer distribution.

Sleep apnoea detection in single channel ECGs by analyzing heart rate dynamics

Effect of intraaortic balloon counter-pulsation on QT dispersion in acute anterior myocardial infarction.

Radioiodinated Ethinylestradiol Derivatives for Estrogen Receptor Targeting Breast Cancer Imaging.

Radiosynthesis and Preclinical Evaluation of 18F-Labeled Estradiol Derivatives with Different Lipophilicity for PET Imaging of Breast Cancer

The biodistribution and imaging of 16 α-[18F]fluoroestradiol (18F-FES) in rats and breast tumor-bearing nude mice

The Biodistribution and Imaging of 16Α-[~(18)F]fluoroestradiol (~(18)F-FES) in Rats and Breast Tumor-Bearing Nude Mice

Current Development of Estrogen Receptor PET Probe-16Α-[18f] Fluoro-17β-estradiol on Molecular Functional Imaging

Radiolabeled AIE Probes As Dual-modality Imaging Agents for PET/NIR-II Fluorescence-Guided Photothermal Therapy

99mTc-labeled iRGD for single-positron emission computed tomography imaging of triple-negative breast cancer

Development of a Novel 18 F-Labeled Probe for PET Imaging of Estrogen Receptor β.

Development of a Novel F-18-Labeled Probe for PET Imaging of Estrogen Receptor beta

A Mitochondria-targeted AIEgen Labelled with <SUP>18</SUP>F for Breast Cancer Cell Imaging and Therapy

Development of a Novel <SUP>18</SUP>F-Labeled Probe for PET Imaging of Estrogen Receptor

eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors

Developing PEGylated Reversed D-Peptide As a Novel HER2-Targeted SPECT Imaging Probe for Breast Cancer Detection

Synthesis and Evaluation of Fluoroethyl Cyclofenil Analogs: Models for Potential Estrogen Receptor Imaging Agent

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial

SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99Mtc-Hynic-h6f in Breast Cancer Mouse Models.

Synthesis and Preclinical Fluorescence Imaging of Dually Functionalized Antibody Conjugates Targeting Endothelin Receptor-Positive Tumors

PET imaging of CCND1 mRNA in human MCF7 estrogen receptor positive breast cancer xenografts with oncogene-specific [64Cu]chelator-peptide nucleic acid-IGF1 analog radiohybridization probes.